EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Sickle Cell Disease and CKD: An Update

Rima S Zahr, Santosh L Saraf

American Journal of Nephrology · 2024 · 55 (1) · 56-71

DOI: 10.1159/000534865 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, online erschienen am 27.10.2023. Verfasst von Rima S Zahr und 1 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology and Hypertension, University of Tennessee Health Science Center, Memphis, Tennessee, USA. Hauptthemen laut MEDLINE: Anemia, Sickle Cell, Kidney Diseases, Kidney Transplantation, Kidney Failure, Chronic. Die Arbeit wurde bisher 25-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Sickle cell disease is an inherited red blood cell disorder that affects approximately 100,000 people in the USA and 25 million people worldwide. Vaso-occlusion and chronic hemolysis lead to dysfunction of vital organ systems, with the kidneys being among the most commonly affected organs. Summary: Early renal manifestations include medullary ischemia with the loss of urine-concentrating ability and hyperfiltration. This can be followed by progressive damage characterized by persistent albuminuria and a decline in the estimated glomerular filtration rate. The risk of sickle nephropathy is greater in those with the APOL1 G1 and G2 kidney risk variants and variants in HMOX1 and lower in those that coinherit α-thalassemia. Therapies to treat sickle cell disease-related kidney damage focus on sickle cell disease-modifying therapies (e.g., hydroxyurea) or those adopted from the nonsickle cell disease kidney literature (e.g., renin-angiotensin-aldosterone system inhibitors), although data on their clinical efficacy are limited to small studies with short follow-up periods. Kidney transplantation for end-stage kidney disease improves survival compared to hemodialysis but is underutilized in this patient population. Key Messages: Kidney disease is a major contributor to early mortality, and more research is needed to understand the pathophysiology and develop targeted therapies to improve kidney health in sickle cell disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anemia, Sickle CellKidney DiseasesKidney TransplantationKidney Failure, ChronicHumansKidneyGlomerular Filtration RateAlbuminuriaApolipoprotein L1

Stichwörter der Autor:innen

AlbuminuriaGlomerular filtration rateKidney diseaseNephropathySickle cell disease

Substanzen

APOL1 protein, humanApolipoprotein L1

Autor:innen und Institutionen

  • Division of Pediatric Nephrology and Hypertension, University of Tennessee Health Science Center, Memphis, Tennessee, USA.
  • Division of Hematology & Oncology, University of Illinois Chicago, Chicago, Illinois, USA.

Förderung

  • NHLBI NIH HHS

Zitieren

APA

Zahr, R. S., & Saraf, S. L. (2024). Sickle Cell Disease and CKD: An Update. American Journal of Nephrology, 55(1), 56-71. https://doi.org/10.1159/000534865

Vancouver

Zahr RS, Saraf SL. Sickle Cell Disease and CKD: An Update. American Journal of Nephrology. 2024;55(1):56-71. doi:10.1159/000534865

BibTeX
@article{Zahr2024,
  author = {Zahr, Rima S and Saraf, Santosh L},
  title = {Sickle Cell Disease and CKD: An Update},
  journal = {American Journal of Nephrology},
  year = {2024},
  volume = {55},
  number = {1},
  pages = {56--71},
  doi = {10.1159/000534865}
}
Kostenlos starten →